| Literature DB >> 21989155 |
Tetsuo Asai1, Kaori Masani, Chizuru Sato, Mototaka Hiki, Masaru Usui, Kotaro Baba, Manao Ozawa, Kazuki Harada, Hiroshi Aoki, Takuo Sawada.
Abstract
A total of 318 Escherichia coli isolates obtained from different food-producing animals affected with colibacillosis between 2001 and 2006 were subjected to phylogenetic analysis: 72 bovine isolates, 89 poultry isolates and 157 porcine isolates. Overall, the phylogenetic group A was predominant in isolates from cattle (36/72, 50%) and pigs (101/157, 64.3%) whereas groups A (44/89, 49.4%) and D (40/89, 44.9%) were predominant in isolates from poultry. In addition, group B2 was not found among diseased food-producing animals except for a poultry isolate. Thus, the phylogenetic group distribution of E. coli from diseased animals was different by animal species. Among the 318 isolates, cefazolin resistance (minimum inhibitory concentrations: ≥32 μg/ml) was found in six bovine isolates, 29 poultry isolates and three porcine isolates. Of them, 11 isolates (nine from poultry and two from cattle) produced extended spectrum β-lactamase (ESBL). The two bovine isolates produced bla(CTX-M-2), while the nine poultry isolates produced bla(CTX-M-25) (4), bla(SHV-2) (3), bla(CTX-M-15) (1) and bla(CTX-M-2) (1). Thus, our results showed that several types of ESBL were identified and three types of β-lactamase (SHV-2, CTX-M-25 and CTX-M-15) were observed for the first time in E. coli from diseased animals in Japan.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21989155 PMCID: PMC3206820 DOI: 10.1186/1751-0147-53-52
Source DB: PubMed Journal: Acta Vet Scand ISSN: 0044-605X Impact factor: 1.695
Distribution of Escherichia coli isolate phylogenetic groups from diseased animals in Japan between 2001 and 2006
| Phylogenetic group | No. of isolates tested | No. of isolates resistant to cefazolin (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| Cattle | Poultry | Swine | Total | Cattle | Poultry | Swine | Total | |
| A | 36 | 44 | 101 | 181 | 3 (8.3) | 21 (47.7) | 2 (2.0) | 26 (14.4) |
| B1 | 18 | 4 | 9 | 31 | 2 (11.1) | 1 (25.0) | 0 (0) | 3 (9.7) |
| B2 | 0 | 1 | 0 | 1 | 0 (NA) | 0 (0) | 0 (NA*) | 0 (0) |
| D | 18 | 40 | 47 | 105 | 1 (5.6) | 7 (17.5) | 1 (2.1) | 9 (8.6) |
| Total | 72 | 89 | 157 | 318 | 6 (8.3) | 29 (32.6) | 3 (1.9) | 38 (11.9) |
* NA: not applicable
MICs of β-lactam antibiotics for 38 cefazolin-resistant isolates of E. coli from diseased animals isolated between 2002 and 2006
| MICs (μg/ml) of: | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Animal species | β-lactamase | n | Year isolated | Phylogenetic group | Cefazolin | Cefpodoxime | Cefotaxime | Ceftazidime | Aztreonam | Imipenem | Meropenem |
| (32)* | (8) | (64) | (32) | (32) | (16) | (16) | |||||
| Cattle | CTX-M-2 | 1 | 2003 (1) | A (1) | 256 | >32 | >32 | 4 | 16 | ≤1 | ≤4 |
| CTX-M-2/TEM-1 | 1 | 2003 (1) | B1 (1) | 256 | >32 | >32 | 8 | >16 | ≤1 | ≤4 | |
| CMY-2 | 1 | 2003 (1) | A (1) | 256 | 8 | ≤1 | ≤1 | ≤4 | ≤1 | ≤4 | |
| CMY-2/TEM-1 | 1 | 2002 (1) | D (1) | 256 | >32 | 8 | 16 | ≤4 | ≤1 | ≤4 | |
| TEM-1 | 1 | 2003 (1) | A (1) | 32 | 8 | ≤1 | 2 | ≤4 | ≤1 | ≤4 | |
| ND | 1 | 2002 (1) | B1 (1) | 128 | 16 | ≤1 | 8 | ≤4 | ≤1 | ≤4 | |
| Poultry | CTX-M-2 | 1 | 2006 | A (1) | >512 | >32 | >32 | 2 | ≤4 | ≤1 | ≤4 |
| CTX-M-15/TEM-1 | 1 | 2006 | A (1) | >512 | >32 | >32 | 32 | 8 | ≤1 | ≤4 | |
| CTX-M-25 | 4 | 2005(3), 2006 (1) | A (2), D (2) | >512 | >32 | 16->32 | 2-4 | ≤4-8 | ≤1 | ≤4 | |
| SHV-2 | 3 | 2004 (3) | A (3) | 256-512 | 32->32 | 8-32 | 4-16 | ≤4-8 | ≤1 | ≤4 | |
| CMY-2 | 10 | 2004(1), 2006 (10) | A (5), B1 (1), D (5) | 512->512 | >32 | 4-32 | 8-32 | ≤4-8 | ≤1 | ≤4 | |
| TEM-1 | 7 | 2004 (2), 2005 (5) | A (7) | 64->512 | 16-32 | ≤1-2 | 4-8 | ≤4 | ≤1 | ≤4 | |
| ND | 2 | 2002 (1), 2005 (1) | A (2) | 128-256 | 16-32 | ≤1-2 | 4 | ≤4 | ≤1 | ≤4 | |
| Swine | CMY-2/TEM-1 | 1 | 2004 (1) | A (1) | >512 | >32 | 16 | 32 | 16 | ≤1 | ≤4 |
| ND | 2 | 2002 (1), 2003 (1) | A (1), D (1) | 128-256 | 4-8 | ≤1 | ≤1 | ≤4 | ≤1 | ≤4 | |
* Resistance breakpoint (μg/ml) defined by CLSI guideline.